Liminatus Pharma Reports Stockholders’ Equity Above $2.5M After Merger

What Happened Liminatus Pharma, Inc. (LIMN) filed a Form 8-K on July 30, 2026, reporting that, as a result of its previously announced merger with InnocsAI LLC, the company believes its stockholders’ equity is now in excess of $2.5 million. The company is awaiting a compliance determination from The Nasdaq Stock Market LLC and disclosed that Nasdaq will continue to monitor its ongoing compliance.

Key Details

• Filing date: July 30, 2026 (Current Report on Form 8-K).
• Triggering event: Merger with InnocsAI LLC, after which the company believes stockholders’ equity exceeds $2.5 million.
• Regulatory status: Liminatus is awaiting Nasdaq’s compliance determination; Nasdaq will continue to monitor and could subject the company to future delisting if it does not show compliance at the time of its next periodic report.
• The company included forward‑looking statement language warning outcomes may differ and that there is no assurance Nasdaq will accept the company’s plan or that compliance will be regained.

Why It Matters This update matters because meeting Nasdaq’s minimum stockholders’ equity threshold is a key condition for continued listing. While the company believes it now exceeds the $2.5M equity threshold following the merger, final determination rests with Nasdaq. Investors should watch for Nasdaq’s formal determination and the company’s next periodic report, since failure to demonstrate continued compliance could lead to future delisting proceedings.